March 29 (Reuters) - Biotech company Aveo Pharmaceuticals Inc will pay $4 million to settle civil charges that it misled investors about U.S. regulators' concerns involving its drug to treat kidney cancer, the Securities and Exchange Commission said on Tuesday.
